The Traderszone Network

Published in TZ Latest News 9 October, 2016 by The TZ Newswire Staff

ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP